Track topics on Twitter Track topics that are important to you
One of the main side-effects of tacrolimus in solid organ transplanted patients is post transplant diabetes mellitus (PTDM). It is not known if different pharmacokinetic properties influence the risk of developing PTDM. It is possible that it either is high peak concentrations of high overall systemic exponation that is responsible for the effect on insulin secretion. With the new slow-release formulation of tacrolimus (Advagraf) a different pharmacokinetic profile is introduced to patients and it is of interest to investigate if this affects insulin secretion and insulin sensitivity of patients.
Hypothesis: The pharmacokinetic profile of tacrolimus affects the insulin secretion in renal transplant recipients.
The primary objective is to compare insulin secretion (Secr2.phase) between the two different formulations of Tac.
Secondary objectives are to compare the effect of the two formulations on Secr1.phase, insulin sensitivity and to investigate possible associations with individual systemic tacrolimus exposures.
Twenty adult kidney transplanted patients treated with Prograf® twice daily or Advagraf® once daily will be included in the study. Eligible patients may be included in a stable posttransplant phase (no Tac dose adjustments or acute rejection episodes the preceding 2 weeks). A 3-hour hyperglycaemic clamp will be performed while patients are treated with their standard Tac formulation and repeated 4-6 weeks after switching to the alternative Tac formulation. The clamp investigation will be done after administration of the morning dose of Tac. Samples for measurement of Tac whole blood concentrations will be drawn for all patients up to 24 hours after morning Tac dosing. It is not mandatory for all patients to perform full 24 hour pharmacokinetic investigations.
Switching to the alternative Tac formulation will be performed in a 1:1 daily dose ratio and subsequently adjusted according to centre protocol for trough concentrations (5-10 ng/mL). Patients will meet for trough concentration measurements at Rikshospitalet for appropriate dose adjustment in the period between the two investigations days.
The patients will primarily be recruited from the great-Oslo area and all study visits will be performed at Rikshospitalet. Patients will otherwise follow standard post transplant procedures at their local hospital during the study period. Patients included in other clinical trials are also eligible for inclusion in the present study as long as they are not treated with investigational drugs.
Informed consent will be obtained according to the Declaration of Helsinki and ICH-GCP guidelines. Patients and investigator will sign the patient information which will be kept on file. The patient will receive a copy of the patient information. Patient data will be recorded in Case Report Forms (CRF) and all information will be handled confidentially. Any complications will be recorded.
Glucose clamp calculations
Lean body mass (lbm) is estimated using Hume's formula  which correlates well with tritiated water or electrical bioimpedance measures . Secr1.phase is calculated as the area under serum insulin vs. time curve (AUC, trapezoidal rule) during the first 10 min of the clamp procedure, and Secr2.phase is calculated as the insulin AUC during the last hour (120-180 min) of the clamp procedure. The same calculations were also performed for C-peptide concentrations. Glucose disposal rate (GDR) is calculated from the amount of glucose infused during the last hour of the clamp. The IS index (ISI) is calculated as GDR [mmol/kg (lbm)*min] divided by mean serum insulin (pmol/l) in the same period. Glucose clearance is calculated as ISI divided by mean serum glucose during the last 60 min of the clamp .
Nonlinear mixed effects modeling (NONMEM software version VI and Intel Fortran (version 8) compilation tool) will be used to analyze the dose-concentration-time data for Tac using a population approach. The pharmacokinetic profile data will be used to develop a pharmacokinetics model including the effect of major covariates (e.g. age, gender, body size, renal function, hematocrit, acute rejection status etc.) on CL/F and V/F from the 24-hour pharmacokinetics investigations. If applicable additional trough concentration data from the routine follow-up of the patients in the study will be used to develop the model.
Exclusion of patient data will only be allowed if Tac concentrations have not been able to be measured accurately or in case of unavailable information that may interfere with pharmacokinetic evaluation, e.g. exact blood sampling time or dose given.
The POSTHOC, MAXEVAL=0 option in NONMEM will be used to estimate individual AUC0-24 and half-lives for each individual. Actually measured Ctrough, Cmax and Tmax values will also be used to describe the pharmacokinetic properties of the patients.
Based on the assumption that a 15% relative change in insulin secretion between the two formulations are clinically relevant and a relative standard deviation of 25% 20 patients are needed to assure a power of 80% at a 5% significance level. Patients that drop-out during the study will be substituted.
The primary end-point will be analyzed per-protocol by comparing the ratio of insulin sensitivity (Secr2.phase) for the two formulations. Data will be transformed to obtain normal distribution if appropriate.
Secondary endpoints will be analyzed as follows:
- Insulin Secr1.phase
- Insulin sensitivity index (ISI)
- Association between insulin Secr2.phase, Secr1.phase and ISI and systemic exposure of Tac (derived from individual NONMEM estimations)
- All analysis above also performed for C-peptide
Allocation: Non-Randomized, Control: Active Control, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention
Post Transplant Diabetes Mellitus
Oslo univeristy hospital, Rikshospitalet
University of Oslo School of Pharmacy
Published on BioPortfolio: 2014-08-27T03:14:59-0400
The trial is conducted in patients who have received a liver transplant, were prescribed tacrolimus to prevent organ rejection and developed diabetes from 3 month post-transplantation onwa...
This clinical research studies the physiology and immunology of new-onset post-transplant diabetes mellitus in patients undergoing allogeneic stem cell transplantation. Oral glucose tolera...
New onset diabetes after renal transplantation (NODAT) is a common and severe complication negatively influencing graft and patient survival. Cyclosporine (CsA) and Tacrolimus are the basi...
The purpose of this study is to evaluate two groups of kidney transplant recipients, to determine the proportion of patients that achieve therapeutic blood concentrations of tacrolimus by ...
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to assess t...
Post-transplantation diabetes mellitus (PTDM) is a serious metabolic complication after kidney transplantation. The aim of this study was to explore the association of clinical variables and five sele...
The objective of the current study was to explore the role of ABCB1 and CYP3A5 genetic polymorphisms in predicting the bioavailability of tacrolimus and the risk for post-transplant diabetes. Artifici...
Lung transplant immunosuppression regimens generally include the calcineurin inhibitor tacrolimus. We hypothesized that mean residual expression (MRE) of calcineurin-dependent genes assesses rejection...
Tacrolimus is the most widely used immunosuppressant in solid organ transplant patients. The cytochrome P450 3A5 (CYP3A5) has been proved to be associated with tacrolimus dose requirement. Molecular d...
Concern has been raised over using tacrolimus for maintenance immunosuppression in kidney transplant recipients with known allergies to macrolide antibiotics, such as azithromycin, clarithromycin and ...
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY.
Urination of a large volume of urine with an increase in urinary frequency, commonly seen in diabetes (DIABETES MELLITUS; DIABETES INSIPIDUS).
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
A strain of Rattus norvegicus which is a model for spontaneous insulin-dependent diabetes mellitus (DIABETES MELLITUS, INSULIN-DEPENDENT).
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...